We came across a bullish thesis on BioNTech SE on Lux Opes Research’s Substack. In this article, we will summarize the bulls’ thesis on BNTX. BioNTech SE's share was trading at $118.00 as of January 26th. BNTX’s trailing and forward P/E were 166.87 and 7.04 respectively according to Yahoo Finance. Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here's Why Pressmaster/Shutterstock.com BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseas ...

合作与许可协议 - Janux Therapeutics与百时美施贵宝达成合作及全球独家许可协议 公司将获得高达5000万美元的预付款和近期里程碑付款 潜在总付款额约达8亿美元 并包含全球产品销售的分成 [1] - 根据协议 Janux将负责完成临床前开发直至提交研究性新药申请 百时美施贵宝将负责后续的开发和商业化工作 [2] - 此次合作旨在增强公司开发针对实体瘤的新型免疫疗法的能力 公司将在首个1期临床研究中积极支持百时美施贵宝 [3] 公司平台验证与历史合作 - 此次合作被视为对公司肿瘤激活平台实力的重要验证 分析师认为大型药企的持续兴趣强化了该平台的差异化优势 [4] - 公司在2020年曾与默克公司就T细胞衔接器免疫疗法达成合作 当时公司有资格就每个靶点获得高达5.005亿美元的预付款和里程碑付款以及销售分成 默克负责合作期间的研发资金 [5] 近期临床重点与股价表现 - 分析师指出 2026年的重点仍是JANX007扩展队列的临床数据更新 这对重获市场对该项目的信心至关重要 同时关注JANX008的更新 包括潜在的剂量递增数据和为剂量扩展选择的肿瘤 [6] - 公司股价近期表现疲弱 目前交易价格仅比20日简单移动平均线高1.6% 但比50日简单移动平均线低27.8% 过去12个月股价下跌约66.97% 更接近52周低点 [7] 技术指标与分析师观点 - 技术指标显示相对强弱指数为31.96 处于中性区域 而MACD位于信号线上方 显示看涨动能 两者结合表明股票动能信号不一 [8] - 股票获得“买入”评级 平均目标价为61.76美元 近期分析师行动包括：Clear Street下调评级至持有并将目标价降至12.00美元 Piper Sandler维持超配评级但将目标价降至30.00美元 巴克莱维持超配评级但将目标价降至29.00美元 [9] 市场评分与价格走势 - Benzinga Edge评分卡显示公司动量评分为1.4 为看涨 表明其表现优于大盘 但极低的价值评分警告股价已反映完美预期 [10] - 根据Benzinga Pro数据 公司股价在周四上涨7.69% 收于14.29美元 [11]

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts public offering of 5,366,726 units. Each unit consists of one common share (or one pre-funded warrant (“Pre-Funded Warrant”) in lieu thereof) and one warrant (the “Warran ...

OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy NANTES, France – September 26, 2025, 7:00 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), Inserm Transfert (on behalf of Inserm, a French public organization dedicated to human health), and Nantes University today announce the signing of a strategic partnership agreement aimed at accelerating the development of innovative projects in the fields of immuno ...